Form 4 for ARWR ARROWHEAD PHARMACEUTICALS, INC.
Accepted 2022-12-20 00:00:00 ET · period of report 2022-12-16 · accession 0001209191-22-062241 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2022-12-20 | 2022-12-16+ | ARWR | Anzalone Christopher Richard | CEO, Dir | A - Grant | $0.00 | +252.4K | 3.72M | +7% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-12-16 | A | A | 18,375 | $0.00 | 3,486,689 | D | — | — | (F1) Represents shares of stock which vested on the date of issuance. |
| 2 | Common | Common Stock | 2022-12-20 | A | A | 234,025 | $0.00 | 3,720,714 | D | — | — | (F2) Includes 93,610 shares underlying restricted stock units, which will vest in four equal installments, with a commencement date of 12/20/22. Includes 140,415 underlying restricted stock units, that may be earned based on the achievement of certain performance and/or market-based goals. If the goals are not met within the required time periods, the awards will be forfeited in part of in whole. (F3) Includes a total of 1,789,697 shares underlying restricted stock units that may be earned based on the achievement of certain performance and/or market-based goals. If the goals are not met within the required time periods, the awards will be forfeited in part or in whole. |